Phase 1
N=40
Effect of Number of Remote Limb Ischemic Conditioning Cycles on Learning Enhancement
Healthy, Young Adults
Bottom Line
View on ClinicalTrials.gov: NCT03512041 ↗Enrolled (actual)
40
Serious AEs
0.0%
Results posted
Aug 2019
Primary outcome: Primary: Balance Score — 9.9; 11.5; 7.0; 11.3 seconds — p=0.172
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 1
- Interventions
- RLIC - 5 cycles (Behavioral); RLIC - 4 Cycles (Behavioral); RLIC - 3 Cycles (Behavioral); Sham conditioning (Behavioral); Balance training (Behavioral); Arm training (Behavioral); Sequence production training (Behavioral)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- Washington University School of Medicine
- Primary completion
- Feb 2018
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Balance Score |
9.9; 11.5; 7.0; 11.3 | 0.172 |
| PRIMARY Cup Stacking Score |
-22.2; -14.9; -11.9; -10.1 | 0.169 |
| PRIMARY Discrete Sequence Production Task Score |
-3.1; -2.9; -2.6; -2.9 | 0.501 |
Summary
The purpose of this research study is to determine the effect of number of remote limb ischemic conditioning (RLIC) cycles on enhancing learning in neurologically intact young adults.
Eligibility Criteria
Inclusion Criteria
- Between the age of 18 and 40 years
Exclusion Criteria
- History of neurological condition (i.e. stroke, Alzheimer's disease, Parkinson's disease), ADD, ADHD, balance impairment, or vestibular disorder
- History of sleep apnea
- History of lower extremity condition, injury, or surgery which could compromise performance on motor training task
- Any extremity soft tissue, orthopedic, or vascular injury (i.e. peripheral vascular disease) which may contraindicate RLIC
- Any cognitive, sensory, or communication problem that would prevent completion of the study
- Current intensive weight lifting or interval training exercise
- Current substance abuse or dependence
- Current use of medication with selective serotonin-reuptake inhibitors.
- Unwillingness to travel for all study visits
Data sourced from ClinicalTrials.gov (NCT03512041). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.